Soligenix Inc. Targets Key Milestones in Rare Disease Pipeline with Potential $2 Billion Global Opportunity
Soligenix Inc. outlines significant clinical and strategic milestones for its rare disease therapies, including Phase 3 FLASH 2 results for HyBryte(TM) and updates on psoriasis and Behçet’s Disease treatments, projecting over $90 million in U.S. annual sales and global opportunities exceeding $2 billion.
